The post Generic Drugs Are The Physical Manifestation Of Lifesaving Abundance appeared on BitcoinEthereumNews.com. CHICAGO – JULY 23: Lipitor tablets sit in a tray at a Pharmacy July 23, 2008 in Chicago, Illinois. Pfizer, the world’s biggest drug maker and manufacturer of the cholesterol drug Lipitor, said today its second quarter profit rose to $2.78 billion. Lipitor is the world’s top-selling drug. (Photo by Scott Olson/Getty Images) Getty Images Ludwig von Mises long ago observed that the notion of luxury is entirely historical. The previous truth is important to remember as Sens. Rick Scott (R-FL) and Kirsten Gillibrand (D-NY) take aim at generic drugs. For the senators to question the safety and quality of generics whether produced stateside or overseas is for them to question the brilliant evolution of all market advances that ultimately expand access to goods formerly inaccessible to all but the richest of the rich, if at all. Cars once driven by the very rich were rendered plentiful by Henry Ford given his desire to manufacture them for “the great multitude.” The first IBM mainframe computer in the 1960s fetched over $1 million dollars, only for visionaries like Michael Dell to become billionaires by virtue of mass-producing computers similarly available to “the great multitude.” In 1983, Motorola launched the first mobile phone for $3,995, while today we have supercomputers in our pockets that transmit calls for us, in addition to thousands of other features. Which is why pharmaceutical advance is so important. No doubt politicians can and do blanch at the dollars expended on innovations meant to mitigate the horrors of cancer, heart disease, Alzheimer’s and countless other maladies, but the people invariably benefit. And this is true even if it’s similarly true that initial pharmaceutical leaps gift the very few very well to do with drugs not available to the broader population. We should cheer such an outcome, and for… The post Generic Drugs Are The Physical Manifestation Of Lifesaving Abundance appeared on BitcoinEthereumNews.com. CHICAGO – JULY 23: Lipitor tablets sit in a tray at a Pharmacy July 23, 2008 in Chicago, Illinois. Pfizer, the world’s biggest drug maker and manufacturer of the cholesterol drug Lipitor, said today its second quarter profit rose to $2.78 billion. Lipitor is the world’s top-selling drug. (Photo by Scott Olson/Getty Images) Getty Images Ludwig von Mises long ago observed that the notion of luxury is entirely historical. The previous truth is important to remember as Sens. Rick Scott (R-FL) and Kirsten Gillibrand (D-NY) take aim at generic drugs. For the senators to question the safety and quality of generics whether produced stateside or overseas is for them to question the brilliant evolution of all market advances that ultimately expand access to goods formerly inaccessible to all but the richest of the rich, if at all. Cars once driven by the very rich were rendered plentiful by Henry Ford given his desire to manufacture them for “the great multitude.” The first IBM mainframe computer in the 1960s fetched over $1 million dollars, only for visionaries like Michael Dell to become billionaires by virtue of mass-producing computers similarly available to “the great multitude.” In 1983, Motorola launched the first mobile phone for $3,995, while today we have supercomputers in our pockets that transmit calls for us, in addition to thousands of other features. Which is why pharmaceutical advance is so important. No doubt politicians can and do blanch at the dollars expended on innovations meant to mitigate the horrors of cancer, heart disease, Alzheimer’s and countless other maladies, but the people invariably benefit. And this is true even if it’s similarly true that initial pharmaceutical leaps gift the very few very well to do with drugs not available to the broader population. We should cheer such an outcome, and for…

Generic Drugs Are The Physical Manifestation Of Lifesaving Abundance

CHICAGO – JULY 23: Lipitor tablets sit in a tray at a Pharmacy July 23, 2008 in Chicago, Illinois. Pfizer, the world’s biggest drug maker and manufacturer of the cholesterol drug Lipitor, said today its second quarter profit rose to $2.78 billion. Lipitor is the world’s top-selling drug. (Photo by Scott Olson/Getty Images)

Getty Images

Ludwig von Mises long ago observed that the notion of luxury is entirely historical. The previous truth is important to remember as Sens. Rick Scott (R-FL) and Kirsten Gillibrand (D-NY) take aim at generic drugs. For the senators to question the safety and quality of generics whether produced stateside or overseas is for them to question the brilliant evolution of all market advances that ultimately expand access to goods formerly inaccessible to all but the richest of the rich, if at all.

Cars once driven by the very rich were rendered plentiful by Henry Ford given his desire to manufacture them for “the great multitude.” The first IBM mainframe computer in the 1960s fetched over $1 million dollars, only for visionaries like Michael Dell to become billionaires by virtue of mass-producing computers similarly available to “the great multitude.” In 1983, Motorola launched the first mobile phone for $3,995, while today we have supercomputers in our pockets that transmit calls for us, in addition to thousands of other features.

Which is why pharmaceutical advance is so important. No doubt politicians can and do blanch at the dollars expended on innovations meant to mitigate the horrors of cancer, heart disease, Alzheimer’s and countless other maladies, but the people invariably benefit. And this is true even if it’s similarly true that initial pharmaceutical leaps gift the very few very well to do with drugs not available to the broader population. We should cheer such an outcome, and for obvious reasons.

As the formerly inaccessible car, computer, and mobile phone make blindingly plain, the luxuries of the very rich foretell what we’ll all enjoy if markets are free. It’s that simple.

Which is the point of generic drugs. They’re brilliant pharmaceutical representations of what’s true in all walks of profit-motivated life. What’s expensive in the near-term, and as pharmaceutical companies recoup the enormous costs associated with funding their intrepid leaps, eventually is not.

All of which helps explain why 90 percent of pharmaceutical prescriptions filled are generic. It’s an essential progression.

Which is why pushback against Sens. Scott and Gillibrand is so necessary. For them to attack generic drugs, and in particular foreign-produced generics is for the senators to attack a progression that has long democratized access to life-enhancing and life-saving drugs. Worse, it’s an attack on the evolution of all market advances that are invariably an effect of globalized production.

At which point it’s quite simply odd that Scott would call into question the validity of the FDA’s inspections of foreign generics. The questioning implies an easy FDA that is belied by history, and that Republicans have long criticized as too stringent.

For now, healthcare and the drugs associated with it are frequently expensive. Which is the point. What’s great has to be initially expensive, but much more importantly, what’s inexpensive and accessible to all must initially be quite costly.

Thank goodness for the globalized production that eventually turns costly scarcity into abundance. Scott and Gillibrand should be thankful too, and retrieve legislation meant to suffocate the democratization of what improves life, and often saves it too.

Source: https://www.forbes.com/sites/johntamny/2025/10/28/generic-drugs-are-the-physical-manifestation-of-democratized-abundance/

Market Opportunity
Oasis Logo
Oasis Price(ROSE)
$0.01464
$0.01464$0.01464
-1.87%
USD
Oasis (ROSE) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Is Doge Losing Steam As Traders Choose Pepeto For The Best Crypto Investment?

Is Doge Losing Steam As Traders Choose Pepeto For The Best Crypto Investment?

The post Is Doge Losing Steam As Traders Choose Pepeto For The Best Crypto Investment? appeared on BitcoinEthereumNews.com. Crypto News 17 September 2025 | 17:39 Is dogecoin really fading? As traders hunt the best crypto to buy now and weigh 2025 picks, Dogecoin (DOGE) still owns the meme coin spotlight, yet upside looks capped, today’s Dogecoin price prediction says as much. Attention is shifting to projects that blend culture with real on-chain tools. Buyers searching “best crypto to buy now” want shipped products, audits, and transparent tokenomics. That frames the true matchup: dogecoin vs. Pepeto. Enter Pepeto (PEPETO), an Ethereum-based memecoin with working rails: PepetoSwap, a zero-fee DEX, plus Pepeto Bridge for smooth cross-chain moves. By fusing story with tools people can use now, and speaking directly to crypto presale 2025 demand, Pepeto puts utility, clarity, and distribution in front. In a market where legacy meme coin leaders risk drifting on sentiment, Pepeto’s execution gives it a real seat in the “best crypto to buy now” debate. First, a quick look at why dogecoin may be losing altitude. Dogecoin Price Prediction: Is Doge Really Fading? Remember when dogecoin made crypto feel simple? In 2013, DOGE turned a meme into money and a loose forum into a movement. A decade on, the nonstop momentum has cooled; the backdrop is different, and the market is far more selective. With DOGE circling ~$0.268, the tape reads bearish-to-neutral for the next few weeks: hold the $0.26 shelf on daily closes and expect choppy range-trading toward $0.29–$0.30 where rallies keep stalling; lose $0.26 decisively and momentum often bleeds into $0.245 with risk of a deeper probe toward $0.22–$0.21; reclaim $0.30 on a clean daily close and the downside bias is likely neutralized, opening room for a squeeze into the low-$0.30s. Source: CoinMarketcap / TradingView Beyond the dogecoin price prediction, DOGE still centers on payments and lacks native smart contracts; ZK-proof verification is proposed,…
Share
BitcoinEthereumNews2025/09/18 00:14
Fed Decides On Interest Rates Today—Here’s What To Watch For

Fed Decides On Interest Rates Today—Here’s What To Watch For

The post Fed Decides On Interest Rates Today—Here’s What To Watch For appeared on BitcoinEthereumNews.com. Topline The Federal Reserve on Wednesday will conclude a two-day policymaking meeting and release a decision on whether to lower interest rates—following months of pressure and criticism from President Donald Trump—and potentially signal whether additional cuts are on the way. President Donald Trump has urged the central bank to “CUT INTEREST RATES, NOW, AND BIGGER” than they might plan to. Getty Images Key Facts The central bank is poised to cut interest rates by at least a quarter-point, down from the 4.25% to 4.5% range where they have been held since December to between 4% and 4.25%, as Wall Street has placed 100% odds of a rate cut, according to CME’s FedWatch, with higher odds (94%) on a quarter-point cut than a half-point (6%) reduction. Fed governors Christopher Waller and Michelle Bowman, both Trump appointees, voted in July for a quarter-point reduction to rates, and they may dissent again in favor of a large cut alongside Stephen Miran, Trump’s Council of Economic Advisers’ chair, who was sworn in at the meeting’s start on Tuesday. It’s unclear whether other policymakers, including Kansas City Fed President Jeffrey Schmid and St. Louis Fed President Alberto Musalem, will favor larger cuts or opt for no reduction. Fed Chair Jerome Powell said in his Jackson Hole, Wyoming, address last month the central bank would likely consider a looser monetary policy, noting the “shifting balance of risks” on the U.S. economy “may warrant adjusting our policy stance.” David Mericle, an economist for Goldman Sachs, wrote in a note the “key question” for the Fed’s meeting is whether policymakers signal “this is likely the first in a series of consecutive cuts” as the central bank is anticipated to “acknowledge the softening in the labor market,” though they may not “nod to an October cut.” Mericle said he…
Share
BitcoinEthereumNews2025/09/18 00:23
Stronger capital, bigger loans: Africa’s banking outlook for 2026

Stronger capital, bigger loans: Africa’s banking outlook for 2026

African banks spent 2025 consolidating, shoring up capital, tightening risk controls, and investing in digital infrastructure, following years of macroeconomic
Share
Techcabal2026/01/14 23:06